1. Scrip
  2. >>Business

Finance Watch: Two New Funds Provide $1.4bn For Health Care Ventures

 
• By Mandy Jackson

Private Company Edition: GHO Capital will invest €975m in pharmaceutical and other opportunities in Europe, but Wellington’s $393m fund is focused on drug discovery and development. Also, Avidity raises $100m and Werewolf launches with $56m.

Finance Watch

Two new private equity funds will make $1.4bn available to health care investment opportunities: London’s Global Health Opportunities, otherwise known as GHO Capital Partners LP, raised €975m ($1.08bn) to back health care companies – including pharmaceutical ventures – in Europe, while Wellington Management’s new $393m fund is entirely focused on private drug discovery and development ventures.

GHO Capital said on 20 November that its GHO Capital Fund II LP exceeded the firm’s €800m goal and doubles the assets it has under management to €2bn, which makes it Europe’s largest health care-focused investment firm

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.